These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21701785)

  • 1. Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria.
    Lin CH; Chen ML; Chen GS; Tai CH; Wu RM
    Hum Genet; 2011 Dec; 130(6):817-27. PubMed ID: 21701785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HTRA2 variations in Taiwanese Parkinson's disease.
    Chen CM; Wu CH; Hsieh CH; Lin CH; Chen IC; Chen YC; Lee LC; Lee CM; Tseng YC; Lee-Chen GJ; Wu YR
    J Neural Transm (Vienna); 2014 May; 121(5):491-8. PubMed ID: 24337630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial defects and neurodegeneration in mice overexpressing wild-type or G399S mutant HtrA2.
    Casadei N; Sood P; Ulrich T; Fallier-Becker P; Kieper N; Helling S; May C; Glaab E; Chen J; Nuber S; Wolburg H; Marcus K; Rapaport D; Ott T; Riess O; Krüger R; Fitzgerald JC
    Hum Mol Genet; 2016 Feb; 25(3):459-71. PubMed ID: 26604148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of GSK-3β mediated phosphorylation in HtrA2 contributes to uncontrolled cell death with Parkinsonian phenotype.
    Bose K; Wagh A; Mishra V; Dutta S; Parui AL; Puja R; Mudrale SP; Kulkarni SS; Gai PB; Sarin R
    Int J Biol Macromol; 2021 Jun; 180():97-111. PubMed ID: 33716130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease.
    Krüger R; Sharma M; Riess O; Gasser T; Van Broeckhoven C; Theuns J; Aasly J; Annesi G; Bentivoglio AR; Brice A; Djarmati A; Elbaz A; Farrer M; Ferrarese C; Gibson JM; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Klein C; Lambert JC; Lesage S; Lin JJ; Lynch T; Mellick GD; de Nigris F; Opala G; Prigione A; Quattrone A; Ross OA; Satake W; Silburn PA; Tan EK; Toda T; Tomiyama H; Wirdefeldt K; Wszolek Z; Xiromerisiou G; Maraganore DM;
    Neurobiol Aging; 2011 Mar; 32(3):548.e9-18. PubMed ID: 20036034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What have PINK1 and HtrA2 genes told us about the role of mitochondria in Parkinson's disease?
    Plun-Favreau H; Gandhi S; Wood-Kaczmar A; Deas E; Yao Z; Wood NW
    Ann N Y Acad Sci; 2008 Dec; 1147():30-6. PubMed ID: 19076428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls.
    Simón-Sánchez J; Singleton AB
    Hum Mol Genet; 2008 Jul; 17(13):1988-93. PubMed ID: 18364387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.
    Fitzgerald JC; Zimprich A; Carvajal Berrio DA; Schindler KM; Maurer B; Schulte C; Bus C; Hauser AK; Kübler M; Lewin R; Bobbili DR; Schwarz LM; Vartholomaiou E; Brockmann K; Wüst R; Madlung J; Nordheim A; Riess O; Martins LM; Glaab E; May P; Schenke-Layland K; Picard D; Sharma M; Gasser T; Krüger R
    Brain; 2017 Sep; 140(9):2444-2459. PubMed ID: 29050400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease.
    Bogaerts V; Nuytemans K; Reumers J; Pals P; Engelborghs S; Pickut B; Corsmit E; Peeters K; Schymkowitz J; De Deyn PP; Cras P; Rousseau F; Theuns J; Van Broeckhoven C
    Hum Mutat; 2008 Jun; 29(6):832-40. PubMed ID: 18401856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variations of Omi/HTRA2 in Chinese patients with Parkinson's disease.
    Wang CY; Xu Q; Weng L; Zhang Q; Zhang HN; Guo JF; Tan LM; Tang JG; Yan XX; Tang BS
    Brain Res; 2011 Apr; 1385():293-7. PubMed ID: 21338583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease.
    Strauss KM; Martins LM; Plun-Favreau H; Marx FP; Kautzmann S; Berg D; Gasser T; Wszolek Z; Müller T; Bornemann A; Wolburg H; Downward J; Riess O; Schulz JB; Krüger R
    Hum Mol Genet; 2005 Aug; 14(15):2099-111. PubMed ID: 15961413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation of Omi/HtrA2 and Parkinson's disease.
    Ross OA; Soto AI; Vilariño-Güell C; Heckman MG; Diehl NN; Hulihan MM; Aasly JO; Sando S; Gibson JM; Lynch T; Krygowska-Wajs A; Opala G; Barcikowska M; Czyzewski K; Uitti RJ; Wszolek ZK; Farrer MJ
    Parkinsonism Relat Disord; 2008 Nov; 14(7):539-43. PubMed ID: 18790661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases.
    Goo HG; Rhim H; Kang S
    Curr Protein Pept Sci; 2017; 18(7):746-757. PubMed ID: 26965693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease.
    Westerlund M; Behbahani H; Gellhaar S; Forsell C; Belin AC; Anvret A; Zettergren A; Nissbrandt H; Lind C; Sydow O; Graff C; Olson L; Ankarcrona M; Galter D
    FASEB J; 2011 Apr; 25(4):1345-52. PubMed ID: 21163861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.
    Plun-Favreau H; Klupsch K; Moisoi N; Gandhi S; Kjaer S; Frith D; Harvey K; Deas E; Harvey RJ; McDonald N; Wood NW; Martins LM; Downward J
    Nat Cell Biol; 2007 Nov; 9(11):1243-52. PubMed ID: 17906618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural-specific deletion of Htra2 causes cerebellar neurodegeneration and defective processing of mitochondrial OPA1.
    Patterson VL; Zullo AJ; Koenig C; Stoessel S; Jo H; Liu X; Han J; Choi M; DeWan AT; Thomas JL; Kuan CY; Hoh J
    PLoS One; 2014; 9(12):e115789. PubMed ID: 25531304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies.
    Kawamoto Y; Kobayashi Y; Suzuki Y; Inoue H; Tomimoto H; Akiguchi I; Budka H; Martins LM; Downward J; Takahashi R
    J Neuropathol Exp Neurol; 2008 Oct; 67(10):984-93. PubMed ID: 18800009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HtrA2/Omi is involved in 6-OHDA-induced endoplasmic reticulum stress in SH-SY5Y cells.
    Luo F; Wei L; Sun C; Chen X; Wang T; Li Y; Liu Z; Chen Z; Xu P
    J Mol Neurosci; 2012 May; 47(1):120-7. PubMed ID: 22246992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis.
    Dagda RK; Chu CT
    J Bioenerg Biomembr; 2009 Dec; 41(6):473-9. PubMed ID: 20012177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial serine protease HTRA2 gene mutation in Asians with coexistent essential tremor and Parkinson disease.
    Chao YX; Ng EY; Foo JN; Liu J; Zhao Y; Tan EK
    Neurogenetics; 2015 Jul; 16(3):241-2. PubMed ID: 25791756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.